Human Recombinant OGN protein, His Tag (V2LY-0526-LY5868)

Name: Human Recombinant OGN protein, His Tag
SKU: V2LY-0526-LY5868
Rating: 5 (1 reviews)

See all OGN antibodies

Compare Online Inquiry

Datasheet

SDS

Request for COA

Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Expressed Host

HEK293 Cells

Protein Species

Human

Tag

His Tag

Protein Construction

This product is Human Recombinant OGN protein, His Tag consist of Amino Acid: 1-298 and predicts a molecular mass of 33.2 kDa.

Molecule Mass

33.2 kDa

Sequence

Amino Acid: 1-298

Species

Human

Formulations & Storage [For reference only, actual COA shall prevail!]

Purity

>95% as determined by SDS-PAGE.

Endotoxin

Please contact us for more information.

Format

Lyophilized

Reconstitution

Allow the vial and reconstitution buffer to equilibrate to room temperature. Briefly centrifuge or tap down the vial to ensure that all lyophilized powder is collected at the bottom of the vial. For the reconstitution of this product, we recommend adding PBS or sterile water to achieve a final antibody concentration of 1 mg/mL. Allow the vial to reconstitute for 10-15 minutes at room temperature with gentle agitation. Avoid vigorous shaking that can cause foaming and antibody denaturation. Aliquot into volumes based on your experiment and store liquid protein at -20°C or -80°C for long time.

Buffer

Lyophilized from sterile PBS

Preservative

None

Storage

Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

More Infomation

Target

Full Name

osteoglycin

Function

Induces bone formation in conjunction with TGF-beta-1 or TGF-beta-2.

Biological Process

Negative regulation of smooth muscle cell proliferationISS:UniProtKB

Cellular Location

Secreted, extracellular space, extracellular matrix

PTM

N- and O-glycosylated. O-glycosylated with a core 1 or possibly core 8 glycan.

Dings, M. P., Manoukian, P., Waasdorp, C., Quik, J. S., Strijker, M., Lodestijn, S. C., ... & Bijlsma, M. F. (2023). Serum levels of iCAF‐derived osteoglycin predict favorable outcome in pancreatic cancer. International Journal of Cancer, 152(3), 511-523.

Qian, C., Zhao, C., Gao, Q., Gu, J., Han, W., Jiang, H., ... & Tu, H. (2022). Reduced Osteoglycin Protein Expression Correlates with Lymph Node Metastasis and Low Differentiation in Human Gastric Cancer.

Qin, W., Zhang, J., Rong, R., Zhang, L., Gao, H., Liu, C., ... & Zhang, Y. (2022). Osteoglycin (OGN) promotes tumorigenesis of pancreatic cancer cell via targeting ID4. Tissue and Cell, 78, 101867.

Nulali, J., Zhan, M., Zhang, K., Tu, P., Liu, Y., & Song, H. (2022). Osteoglycin: an ECM factor regulating fibrosis and tumorigenesis. Biomolecules, 12(11), 1674.

Woessner, M. N., Hiam, D., Smith, C., Lin, X., Zarekookandeh, N., Tacey, A., ... & Levinger, I. (2022). Osteoglycin across the adult lifespan. The Journal of Clinical Endocrinology & Metabolism, 107(4), e1426-e1433.

Zuo, Z., Li, M. H., Zheng, X. H., Yao, W. M., Wang, H., & Li, X. L. (2022). Elevated plasma levels of osteoglycin in cardiovascular patients: A systematic review and meta-analysis. Annals of Palliative Medicine, 11(2), 49805-49505.

Wang, Z., Zhuang, X., Chen, B., & Wei, M. (2021). Osteoglycin knockdown promotes vascular smooth muscle cell proliferation and migration in aortic dissection via the VEGF/VEGFR2 axis. Molecular Medicine Reports, 23(1), 1-1.

González-Salvatierra, S., García-Fontana, C., Andújar-Vera, F., Grau-Perales, A. B., Martínez-Heredia, L., Avilés-Pérez, M. D., ... & García-Fontana, B. (2021). Osteoglycin as a potential biomarker of mild kidney function impairment in type 2 diabetes patients. Journal of Clinical Medicine, 10(10), 2209.

Xu, T., Zhang, R., Dong, M., Zhang, Z., Li, H., Zhan, C., & Li, X. (2019). Osteoglycin (OGN) inhibits cell proliferation and invasiveness in breast cancer via PI3K/Akt/mTOR signaling pathway. OncoTargets and therapy, 10639-10650.

Starup-Linde, J., Viggers, R., & Handberg, A. (2019). Osteoglycin and Bone—a Systematic Review. Current osteoporosis reports, 17, 250-255.

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Human Recombinant OGN protein, His Tag?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols

Related Products

Mouse Anti-OGN (AA 200-298) Recombinant Antibody (CBFYM-3038) (CAT#: CBMAB-M3234-FY)

Rabbit Anti-OGN Recombinant Antibody (CBXO-0153) (CAT#: CBMAB-O0342-CQ)

Mouse Anti-OGN Recombinant Antibody (CBXO-0042) (CAT#: CBMAB-O0343-CQ)

Rat Anti-OGN (AA 20-298) Recombinant Antibody (CBFYM-3037) (CAT#: CBMAB-M3233-FY)

Mouse Anti-OGN Recombinant Antibody (CBXO-0406) (CAT#: CBMAB-O0646-CQ)

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry